Frequently Asked Questions
The global alpha emitters market was valued at USD 370.9 Million in 2022.
The alpha emitters market is expected to grow at a CAGR of 18.5% between 2023 and 2030, reaching USD 1217.0 Million in 2030.
Radium is the leading segment by type of radionuclide, holding over 55% share in value in 2022.
The prostate cancer segment governs the world’s demand for alpha emitters, holding a massive share of over 35% in 2022.
The bone Metastases segment will post the highest CAGR during the forecast period.
North America is fueling the growth of the alpha emitters industry, with an over one-third share in 2022.
Top players are Bayer AG, Alpha Tau Medical Ltd., Fusion Pharmaceuticals, Telix Pharmaceuticals Ltd., and Orano Group.
The growing prevalence of cancer patients is the major market driver.
High capital expenditure is the major market restraint.
Increasing awareness regarding the advantages of alpha emitters.